Kellie Mathis, MD
Colon & Rectal Surgery · Rochester, MNNPI 1770563975
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,339 of the $51,362 with a category attached, or 96.1%. Davol Inc. accounts for 76.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $28,133, more than ten times the $325 reported in 2019. Among colon & rectal surgery clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $2568.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$39K
- BD$12K
- Covidien LP$325
- Dilon Technologies, Inc.$63
Across 9 payments — averaging $2877.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Davol Inc.$23K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Consulting fees$49,33996%
- Speaking & faculty fees$1,9604%
- Food & beverage$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 12 | $39,401 |
| BD | 6 | $11,573 |
| Covidien LP | 1 | $325 |
| Dilon Technologies, Inc. | 1 | $63 |
How this compares
$51,362 in reported general payments places this provider in the 95th percentile of 64 colon & rectal surgery providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 27 | $147 |
| Metronidazole | 29 | $54 |
| Ondansetron Hcl | 17 | $21 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Rochester
- Sherief ShawkiRochester$49K
- David LarsonRochester$14K
- Barbara FollestadRochester$4K
- Brenda MurphyRochester$4K
- William PerryRochester$4K
- Rishi BatraRochester$4K
- Lindsey ZhangRochester$4K
- Ana Sofia Ore CarranzaRochester$3K
- Nicholas McKennaRochester$3K
- Kevin BehmRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.